CareDx, Inc (NASDAQ:CDNA) Shares Acquired by BNP Paribas Financial Markets

BNP Paribas Financial Markets grew its holdings in CareDx, Inc (NASDAQ:CDNA - Free Report) by 29.8% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 64,141 shares of the company's stock after purchasing an additional 14,721 shares during the quarter. BNP Paribas Financial Markets owned approximately 0.12% of CareDx worth $1,373,000 at the end of the most recent quarter.

Several other large investors have also modified their holdings of CDNA. Barclays PLC grew its position in shares of CareDx by 123.8% in the third quarter. Barclays PLC now owns 98,505 shares of the company's stock valued at $3,075,000 after purchasing an additional 54,482 shares during the last quarter. ARS Investment Partners LLC grew its position in shares of CareDx by 6.3% in the fourth quarter. ARS Investment Partners LLC now owns 101,968 shares of the company's stock valued at $2,183,000 after purchasing an additional 6,083 shares during the last quarter. SG Americas Securities LLC grew its position in shares of CareDx by 31.0% in the fourth quarter. SG Americas Securities LLC now owns 24,087 shares of the company's stock valued at $516,000 after purchasing an additional 5,706 shares during the last quarter. Exchange Traded Concepts LLC grew its position in shares of CareDx by 6.7% in the fourth quarter. Exchange Traded Concepts LLC now owns 29,107 shares of the company's stock valued at $623,000 after purchasing an additional 1,816 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC grew its position in shares of CareDx by 59.7% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 327,343 shares of the company's stock valued at $7,008,000 after purchasing an additional 122,356 shares during the last quarter.

Analyst Ratings Changes

CDNA has been the topic of several recent analyst reports. The Goldman Sachs Group reduced their price objective on shares of CareDx from $34.00 to $26.00 and set a "buy" rating on the stock in a research note on Thursday, April 17th. StockNews.com downgraded shares of CareDx from a "buy" rating to a "hold" rating in a research note on Monday, May 5th. HC Wainwright reissued a "neutral" rating and set a $25.00 price objective on shares of CareDx in a research note on Monday, May 5th. Finally, Stephens reissued an "overweight" rating and set a $40.00 price objective on shares of CareDx in a research note on Monday, May 5th. Three investment analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $30.33.

Insider Activity

In other news, Director Peter Maag sold 13,281 shares of the firm's stock in a transaction on Wednesday, April 30th. The shares were sold at an average price of $17.23, for a total value of $228,831.63. Following the transaction, the director now owns 316,743 shares of the company's stock, valued at approximately $5,457,481.89. This trade represents a 4.02% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Christine Cournoyer sold 16,700 shares of the firm's stock in a transaction on Tuesday, May 6th. The shares were sold at an average price of $14.13, for a total transaction of $235,971.00. Following the sale, the director now directly owns 37,045 shares of the company's stock, valued at approximately $523,445.85. The trade was a 31.07% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 59,382 shares of company stock valued at $934,509. Company insiders own 4.90% of the company's stock.

CareDx Stock Up 0.9%

NASDAQ:CDNA opened at $17.70 on Tuesday. The company has a market cap of $985.55 million, a P/E ratio of -6.56 and a beta of 2.27. CareDx, Inc has a fifty-two week low of $12.90 and a fifty-two week high of $34.84. The firm's 50 day moving average is $17.60 and its two-hundred day moving average is $20.88.

CareDx (NASDAQ:CDNA - Get Free Report) last posted its quarterly earnings results on Wednesday, April 30th. The company reported $0.09 earnings per share for the quarter, topping analysts' consensus estimates of $0.06 by $0.03. The company had revenue of $84.69 million for the quarter, compared to the consensus estimate of $84.56 million. CareDx had a negative net margin of 45.90% and a negative return on equity of 53.70%. CareDx's revenue was up 17.6% on a year-over-year basis. During the same quarter last year, the firm posted ($0.03) earnings per share. Research analysts forecast that CareDx, Inc will post -0.9 earnings per share for the current fiscal year.

CareDx Profile

CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.